-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Venetoclax is a once-daily oral therapy that blocks the action of B-cell lymphoma -2 protein (BCL-2), which helps cancer cells survive
Lymphoma
Figure.
NICE issued a positive final evaluation document, recommending the routine use of venclyxto (venetoclax) and azacitidine in the treatment of aggressive acute myeloid leukemia (AML) by the British NHS
leukemia
AML is an aggressive and difficult-to-treat blood cancer with a low survival rate
Diagnosing quality of life
In the UK, approximately 3,200 people are diagnosed with AML each year, which is equivalent to more than 8 new cases per day
In the UK, approximately 3,200 people are diagnosed with AML each year, which is equivalent to more than 8 new cases per day
Venetoclax treatment can be performed at home, reduce patient dependence on blood transfusions, and could mean less susceptible to infection to reduce the number of visits and coronavirus
Infect
Professor Charlie Craddock, Professor of Hematology Oncology at the University of Birmingham, shared: "Venetoclax combined with azacitidine is the most important advancement in the treatment of AML patients and represents a phased change in the treatment of this common blood cancer
Original source:
Original source:https:// href="https://" target="_blank" rel="noopener">https:// https://
